SAN FRANCISCO — Just a little more than half a year ago, Boston Scientific (Marlborough, Mass.) received one of the most monumental approvals of 2015 when it won the FDA nod for its stroke-fighting Watchman device. In that time, the company has been gathering data; seeking reimbursement; and training physicians on how to use the device. Medical Device Daily spoke with Ken Stein, chief medical officer with the Cardiac Rhythm Management business unit at Boston Scientific from the company's booth, during the Transcatheter Cardiovascular Therapeutics annual meeting, to discuss what's next for the technology.